Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Ferrer

Ferrer is the Highest-performing Pharmaceutical Company in the World for Social and Environmental Impact According to B Corp
From Ferrer
Via Business Wire
Ferrer is Recognized for Its Best-in-class Ethics and Compliance Program
From Ferrer
Via Business Wire
Ferrer Advances Research into Progressive Supranuclear Palsy (PSP) with the Inclusion of the First Participant in a Phase II Clinical Trial
From Ferrer
Via Business Wire
The World Health Organization Includes the Cardiovascular Polypill Developed by the Spanish National Centre for Cardiovascular Research and Ferrer in its List of Essential Medicines
From Ferrer
Via Business Wire
Ferrer Allocates, on Average, More Than 40% of its Profits to Social and Environmental Projects for the Third Consecutive Year
From Ferrer
Via Business Wire
Experts Call for Protocols to Speed up Referrals for Pulmonary Hypertension to Specialized Centers
From Ferrer
Via Business Wire
Ferrer Initiates its ADOREXT Extension Study in Amyotrophic Lateral Sclerosis (ALS)
From Ferrer
Via Business Wire
Ferrer Acquires Worldwide Rights to ASN90, an O-GlcNAcase Inhibitor From Asceneuron, Exclusively to Treat Progressive Supranuclear Palsy (PSP)
From Ferrer
Via Business Wire
The Polypill Reduces Cardiovascular Mortality by 33% in Patients Treated After Myocardial Infarction
From Ferrer
Via Business Wire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.